|
Yao JC, Eisner MP, Leary C, et al.Population based study of islet cell carcinoma.Ann Surg Oncol 2007; 14:3492- 500.
|
|
Zhang S, Li YX, Li NS, et al.Octreotide acetate long-acting release (LAR) in the treatment of pancreatic neuroendocrine tumor.Chin Med J 2009; 122:1582-4.
|
|
Ruscica M, Arvigo M, Steffani L, et al.Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression.Curr Mol Med 2012; Aug 31.[Epub ahead of print].
|
|
Kvols LK, Moertel CG, O'Connell MJ, et al.Treatment of the malignant carcinoid syndrome.Evaluation of a long-acting somatostatin analogue.N Engl J Med 1986; 315:663-6.
|
|
Adams DB, Miller JJ, Seraphin KE.Glucagonoma syndrome.J Am Acad Dermatol 2005; 53:690-1.
|
|
Maurer R, Reubi JC.Somatostatin receptors.JAMA 1985; 253:2741.
|
|
Cakir M, Dworakowska D, Grossman A.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1-molecular pathways.J Cell Mol Med 2010; 14: 2570-84.
|
|
Danila DC, Haidar JN, Zhang X, et al.Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.J Clin Endocrinol Metab 2001; 86:2976-81.
|
|
Weckbecker G, Lewis I, Albert R, et al.Opportunities in somatostatin research: biological, chemical and therapeutic aspects.Nat Rev Drug Discov 2003; 2:999-1017.
|
|
Sharma K, Srikant CB.Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells.Int J Cancer 1998; 76:259-66.
|
|
Lattuada D, Casnici C, Venuto A, et al.The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes.J Neuroimmunol 2002; 133:211-6.
|
|
Sid閞is L, Dub? P, Rinke A.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Oncologist 2012; 17:747-55.
|
|
Reisine T, Wang HL, Guild S.Somatostatin inhibits cAMP-dependent and cAMP-independent calcium influx in the clonal pituitary tumor cell line AtT-20 through the same receptor population.J Pharmacol Exp Ther 1988; 245:225-31.
|